{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T11:15:23Z","timestamp":1790075723283,"version":"4.0.1"},"reference-count":31,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,3,9]],"date-time":"2016-03-09T00:00:00Z","timestamp":1457481600000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Internal Medicine Journal"],"published-print":{"date-parts":[[2016,3]]},"abstract":"Background<\/jats:title>One of the cornerstones of Australia's public health programmes to eliminate tuberculosis (TB) is the identification and treatment of latent tuberculosis infection (LTBI).<\/jats:p><\/jats:sec>Aims<\/jats:title>The main aim of this study is to determine the demographics, compliance, completion rates and adverse events of patients on preventive therapy (PT<\/jats:styled-content>) for LTBI<\/jats:styled-content> at our institution. The secondary aim is to determine the rates of isoniazid (INH<\/jats:styled-content>) hepatotoxicity and identify any contributory factors.<\/jats:p><\/jats:sec>Methods<\/jats:title>The method used was an audit using medical records of 100 consecutive patients (2010\u20132014) treated with PT<\/jats:styled-content> for LTBI<\/jats:styled-content>.<\/jats:p><\/jats:sec>Results<\/jats:title>Seventy\u2010two patients with confirmed LTBI<\/jats:styled-content> started 9 months of INH<\/jats:styled-content> and 22 started 4 months of rifampicin (RIF<\/jats:styled-content>). The median age was 30 years. Half the patients were born in high TB\u2010prevalence countries. Fifty\u2010six per cent were contacts of index cases with confirmed TB, and 26% were pre\u2010immunosuppression. Seventy\u2010seven per cent completed PT<\/jats:styled-content> with adequate compliance. Thirty\u2010three per cent on INH<\/jats:styled-content> and 23% on RIF<\/jats:styled-content> experienced some liver function test (LFT<\/jats:styled-content>) abnormality while on treatment. INH<\/jats:styled-content> was ceased in 3% due to asymptomatic hepatic dysfunction (transaminases >5x upper limit of normal). No patients had permanent liver damage. Significant risk factors for liver dysfunction during PT<\/jats:styled-content> were risk factors for liver disease ( = 8.7; P<\/jats:italic> = 0.03) or abnormal pre\u2010therapy LFT<\/jats:styled-content> ( = 22.4; P<\/jats:italic> < 0.001). No patients developed active TB<\/jats:styled-content>.<\/jats:p><\/jats:sec>Conclusion<\/jats:title>The completion rate of 77% and rate of INH<\/jats:styled-content>\u2010induced hepatic dysfunction of 3% is comparable with the literature. We found no age association with the risk of INH<\/jats:styled-content>\u2010induced hepatic dysfunction; however, there was a significant and linear association with the degree of liver function abnormality during INH<\/jats:styled-content> therapy and the presence of abnormal baseline LFT. Routine LFT<\/jats:styled-content> monitoring allowed early cessation of INH<\/jats:styled-content> in those with significant but asymptomatic hepatitis who did not meet criteria for ATS<\/jats:styled-content>\/CDC LFT<\/jats:styled-content> monitoring.<\/jats:p><\/jats:sec>","DOI":"10.1111\/imj.12979","type":"journal-article","created":{"date-parts":[[2015,12,9]],"date-time":"2015-12-09T16:46:05Z","timestamp":1449679565000},"page":"281-287","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["Baseline abnormal liver function tests are more important than age in the development of isoniazid\u2010induced hepatoxicity for patients receiving preventive therapy for latent tuberculosis infection"],"prefix":"10.1111","volume":"46","author":[{"given":"E. L.","family":"Gray","sequence":"first","affiliation":[{"name":"Department of Respiratory Medicine Prince of Wales Hospital Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. F.","family":"Goldberg","sequence":"additional","affiliation":[{"name":"Department of Respiratory Medicine Prince of Wales Hospital Sydney New South Wales Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,3,9]]},"reference":[{"key":"e_1_2_6_2_1","first-page":"5","article-title":"Management of latent tuberculosis infections in Australia and New Zealand: a review of current practice","volume":"2010","author":"Denholm J","year":"2010","journal-title":"Tuber Res Treat"},{"key":"e_1_2_6_3_1","first-page":"1","article-title":"Targeted tuberculin skin testing and treatment of latent tuberculosis infection","volume":"49","author":"Centers for Disease Control and Prevention","year":"2000","journal-title":"Morb Mortal Wkly Rep"},{"key":"e_1_2_6_4_1","first-page":"847","article-title":"How much isoniazid is needed for prevention of tuberculosis in immunocompetent adults","volume":"3","author":"Comstock G","year":"1999","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_2_6_5_1","first-page":"1235","article-title":"Adherence to treatment for latent tuberculosis infection: systematic review of studies in the US and Canada","volume":"12","author":"Hirsch\u2010Moverman Y","year":"2008","journal-title":"Int J Tuber Lung Dis"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200510-1666ST"},{"key":"e_1_2_6_7_1","volume-title":"The Use of Antibiotics: A Clinical Review of Antibacterial, Antifungal and Antiviral Drugs","author":"Kucers A","year":"1997"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199601270-00008"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199705150-00015"},{"key":"e_1_2_6_10_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.152.1.7599848"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1097\/00007890-199408000-00008"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.21043"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa011110"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1086\/506935"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.20009"},{"key":"e_1_2_6_16_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200404-478OC"},{"key":"e_1_2_6_17_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-149-10-200811180-00003"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200303-390OC"},{"key":"e_1_2_6_19_1","first-page":"S384","article-title":"Tuberculosis contact investigations: outcomes in selected areas of the United States, 1999","volume":"7","author":"Jereb J","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_6_20_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0749-3797(02)00583-4"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.281.11.1014"},{"key":"e_1_2_6_22_1","first-page":"S363","article-title":"Evaluation of tuberculosis contact investigations in California","volume":"7","author":"Sprinson J","year":"2003","journal-title":"Int J Tuberc Lung Dis"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.162.5.2003028"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0048900"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-84-2-181"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-71-6-1113"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.123.1.102"},{"key":"e_1_2_6_28_1","first-page":"486","article-title":"Isoniazid\u2010related fatal hepatitis","volume":"164","author":"Millard P","year":"1996","journal-title":"West J Med"},{"key":"e_1_2_6_29_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.128.1.116"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1093\/clinchem\/46.12.2050"},{"key":"e_1_2_6_31_1","doi-asserted-by":"crossref","first-page":"2027","DOI":"10.1093\/clinchem\/46.12.2027","article-title":"Diagnosis and monitoring of hepatic injury: I. Performance characteristics of laboratory tests","volume":"46","author":"Dufour D","year":"2000","journal-title":"Clin Chem"},{"key":"e_1_2_6_32_1","first-page":"1374","article-title":"Age\u2010related risk of hepatoxicity in the treatment of latent tuberculosis infection: a systematic review","volume":"14","author":"Kunst H","year":"2010","journal-title":"Int J Tuberc Lung Dis"}],"container-title":["Internal Medicine Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fimj.12979","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/imj.12979","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T18:26:02Z","timestamp":1696184762000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/imj.12979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1111\/imj.12979"],"URL":"https:\/\/doi.org\/10.1111\/imj.12979","archive":["Portico"],"relation":{},"ISSN":["1444-0903","1445-5994"],"issn-type":[{"value":"1444-0903","type":"print"},{"value":"1445-5994","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,3]]},"assertion":[{"value":"2015-09-20","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2015-11-23","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2016-03-09","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}